157 related articles for article (PubMed ID: 17237696)
1. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
Garibaldi DC; Adler RA
Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696
[TBL] [Abstract][Full Text] [Related]
2. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling.
Frankfort BJ; Garibaldi DC
Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130
[No Abstract] [Full Text] [Related]
3. Reversible cicatricial ectropion associated with EGFR inhibitors.
Scofield-Kaplan S; Todaro J; Winn BJ
Orbit; 2018 Oct; 37(5):364-367. PubMed ID: 29336655
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
7. Use of amniotic membrane graft in the surgical management of cicatricial ectropion associated with cetuximab therapy.
Vinod K; Diaz V
J Surg Case Rep; 2015 Jan; 2015(1):. PubMed ID: 25576167
[TBL] [Abstract][Full Text] [Related]
8. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.
Takahashi N; Yamada Y; Furuta K; Nagashima K; Kubo A; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y
Cancer Sci; 2015 May; 106(5):604-10. PubMed ID: 25707609
[TBL] [Abstract][Full Text] [Related]
9. Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer.
Jin HD; Blessing NW
Am J Ophthalmol Case Rep; 2020 Sep; 19():100810. PubMed ID: 32642599
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Patel DK
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
[TBL] [Abstract][Full Text] [Related]
12. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target.
Meropol NJ
J Clin Oncol; 2005 Mar; 23(9):1791-3. PubMed ID: 15677698
[No Abstract] [Full Text] [Related]
15. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
16. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
18. A case of ecthyma during therapy with an epidermal growth factor receptor inhibitor.
Mizuno T; Tanegashima T; Suzuki A; Kuze S; Koyama T
Eur J Dermatol; 2014; 24(4):511-2. PubMed ID: 25266748
[No Abstract] [Full Text] [Related]
19. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
20. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien K; Berry S; Ko YJ; Chan KK
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
